Increased prevalence of autoimmune diseases in functional gastrointestinal disorders: case-control study of 23471 primary care patients.

Abstract:

BACKGROUND:There is increasing evidence that impaired mucosal defence mechanisms are implicated in the pathogenesis of the functional gastrointestinal disorders (FGIDs), allowing inappropriate immune activation. AIM:To test the hypothesis that an excess of autoimmune disorders among sufferers, using a large primary care database to examine this. METHODS:Cases were diagnosed with FGIDs - irritable bowel syndrome (IBS), functional dyspepsia (FD), chronic idiopathic constipation (CIC), and multiple FGIDs. Controls were those without FGIDs. Prevalence of autoimmune disorders was compared between cases and controls using odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS:We included 23,471 patients (mean age 51.4 years, 66.1% female). Prevalence of autoimmune disorders was greater among all FGIDs, compared with controls without. In those with FD (OR 1.35; 95% CI 1.12-1.63), CIC (OR 1.75; 95% CI 1.11-2.75), or multiple FGIDs (OR 1.49; 95% CI 1.25-1.77) this was statistically significant after controlling for age and gender. Rheumatological autoimmune disorders were significantly more frequent in those with FD (OR 1.44; 95% CI 1.15-1.80), CIC (OR 1.84; 95% CI 1.08-3.13), or multiple FGIDs (OR 1.53; 95% CI 1.24-1.88), after controlling for age and gender. However, endocrine autoimmune disorders were no more frequent in those with FGIDs, after controlling for age and gender. CONCLUSIONS:In a large sample of primary care patients, there was a significantly higher prevalence of autoimmune disorders among those with FD, CIC, or multiple FGIDs not explained by differences in age or gender. We were unable to control for concomitant drug use, which may partly explain this association.

journal_name

Aliment Pharmacol Ther

authors

Ford AC,Talley NJ,Walker MM,Jones MP

doi

10.1111/apt.12903

subject

Has Abstract

pub_date

2014-10-01 00:00:00

pages

827-34

issue

7

eissn

0269-2813

issn

1365-2036

journal_volume

40

pub_type

杂志文章
  • Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma.

    abstract:BACKGROUND:Deregulation of mammalian target of rapamycin (mTOR) signalling is common in human hepatocellular carcinoma (HCC). AIM:To determine the maximum tolerated dose (MTD) of the oral mTOR inhibitor everolimus in advanced HCC patients. METHODS:Patients with locally advanced or metastatic HCC (Child-Pugh class A o...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/apt.12132

    authors: Shiah HS,Chen CY,Dai CY,Hsiao CF,Lin YJ,Su WC,Chang JY,Whang-Peng J,Lin PW,Huang JD,Chen LT

    更新日期:2013-01-01 00:00:00

  • The effects of propranolol on hepatic encephalopathy in patients with cirrhosis and portal hypertension.

    abstract::Beta adrenoreceptor blocking drugs have been used for the prevention of haemorrhage from oesophageal varices. However, it is possible that these agents, by virtue of their effects on hepatic blood flow, may impair liver function and precipitate hepatic encephalopathy. We have therefore studied the effect of the beta b...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1988.tb00681.x

    authors: Dunk AA,Moore J,Symon A,Dickie A,Sinclair TS,Mowat NA,Brunt PW

    更新日期:1988-04-01 00:00:00

  • One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.

    abstract:BACKGROUND:Triple therapy based upon omeprazole, amoxycillin and clarithromycin for 7 days is the reference treatment used in France for the eradication of Helicobacter pylori. However, optimal dosages of omeprazole and clarithromycin have not been determined. AIMS:To compare four eradication regimens using this treat...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1046/j.1365-2036.1998.00315.x

    authors: Bigard MA,Delchier JC,Riachi G,Thibault P,Barthelemy P

    更新日期:1998-04-01 00:00:00

  • Prospective evaluation of ranitidine bismuth citrate-based triple therapy for the treatment of Helicobacter pylori infection.

    abstract:BACKGROUND:There is a need for effective and inexpensive therapy for Helicobacter pylori with good patient compliance. AIM:To evaluate a simplified twice daily schedule for treating H. pylori. METHODS:Patients infected with H. pylori (positive by CLO- and 13C-urea breath tests [UBT]) and not previously treated with a...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.1999.00509.x

    authors: Mönkemüller KE,Hirschowitz BI

    更新日期:1999-05-01 00:00:00

  • The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy.

    abstract:AIM:To investigate the efficacy of two omeprazole triple therapies for the eradication of Helicobacter pylori, ulcer healing and ulcer relapse during a 6-month treatment-free period in patients with active duodenal ulcer. METHODS:This was a double-blind, randomized study in 15 centres across Canada. Patients (n = 149)...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1046/j.1365-2036.1999.00471.x

    authors: Zanten SJ,Bradette M,Farley A,Leddin D,Lind T,Unge P,Bayerdörffer E,Spiller RC,O'Morain C,Sipponen P,Wrangstadh M,Zeijlon L,Sinclair P

    更新日期:1999-03-01 00:00:00

  • The association between markers of liver injury and clinical outcomes in patients with COVID-19 in Wuhan.

    abstract:BACKGROUND:The outbreak of coronavirus disease 2019 (COVID-19) is a critical challenge for public health. The effect of COVID-19 on liver injury has not been fully established. AIMS:To evaluate the dynamic changes in liver function and the relationship between liver damage and prognosis in patients with COVID-19. MET...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.15962

    authors: Huang H,Chen S,Li H,Zhou XL,Dai Y,Wu J,Zhang J,Shao L,Yan R,Wang M,Wang J,Tu Y,Ge M

    更新日期:2020-09-01 00:00:00

  • A double-blind, placebo-controlled study of the efficacy and safety of non-prescription ranitidine 75 mg in the prevention of meal-induced heartburn.

    abstract:BACKGROUND:Ranitidine 75 mg (Zantac 75) has been shown to be effective for the treatment of pre-existing heartburn symptoms. AIM:To compare the efficacy of dosing ranitidine 75 mg or placebo 30 min prior to a proven heartburn-provoking meal in completely preventing or reducing subsequent heartburn symptoms. METHODS:A...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.1999.00505.x

    authors: Pappa KA,Williams BO,Payne JE,Buaron KS,Mussari KL,Ciociola AA

    更新日期:1999-04-01 00:00:00

  • A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients.

    abstract:BACKGROUND:Treatment options for non-alcoholic steatohepatitis (NASH) are limited. Weight loss remains the most recommended therapy. Orlistat is an effective adjunct to dietary weight loss therapy. AIM:To evaluate the efficacy of orlistat, given for 6 months to patients with obesity and biopsy confirmed NASH. METHODS...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2004.02153.x

    authors: Harrison SA,Fincke C,Helinski D,Torgerson S,Hayashi P

    更新日期:2004-09-15 00:00:00

  • Histamine receptor antagonists and incident colorectal adenomas.

    abstract:BACKGROUND:Prior studies suggest that histamines may modulate the development of colorectal neoplasia. AIM:To assess whether histamine receptor antagonist use was associated with adenoma formation. METHODS:Patients (n = 2366) were drawn from three adenoma chemoprevention trials. All underwent baseline colonoscopy wit...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1111/j.1365-2036.2005.02529.x

    authors: Robertson DJ,Burke CA,Schwender BJ,Wargovich MJ,Greenberg ER,Sandler RS,Ahnen DJ,Rothstein R,Mott LA,Baron JA

    更新日期:2005-07-15 00:00:00

  • Efficacy of a standard United Kingdom oral rehydration solution (ORS) and a hypotonic ORS assessed by human intestinal perfusion.

    abstract::Human triple-lumen intestinal perfusion was used to compare water and solute absorption from the oral rehydration solution (ORS) most widely used in the United Kingdom and a new experimental hypotonic ORS (HYPO-ORS). HYPO-ORS (osmolality 210 mOsm/kg) promoted significantly greater water absorption than UK-ORS (7.03 +/...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.1989.tb00249.x

    authors: Hunt JB,Elliott EJ,Farthing MJ

    更新日期:1989-12-01 00:00:00

  • Review article: is stringent control of gastric pH useful and practical in GERD?

    abstract::As the relative efficacy of therapeutic agents in the treatment of gastro-oesophageal reflux disease is related to how consistently and completely gastric acid secretion is suppressed, intragastric pH monitoring is a useful tool in stratifying therapies. If there is no acid in the stomach, there can be none to reflux ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2004.02135.x

    authors: Kahrilas PJ

    更新日期:2004-10-01 00:00:00

  • Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss.

    abstract:BACKGROUND:Serum hepatitis B virus (HBV) RNA may reflect intrahepatic HBV replication. Novel anti-viral drugs have shown potent HBV RNA decline without concomitant hepatitis B surface antigen (HBsAg) decrease. How this relates to off-treatment response is yet unclear. AIM:To study the degree of on-treatment viral anti...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.16172

    authors: Brakenhoff SM,de Man RA,Boonstra A,van Campenhout MJH,de Knegt RJ,van Bömmel F,van der Eijk AA,Berg T,Hansen BE,Janssen HLA,Sonneveld MJ

    更新日期:2021-01-01 00:00:00

  • Clinical trial: oral zinc in hepatic encephalopathy.

    abstract:BACKGROUND:Hepatic encephalopathy has a negative effect on patient health-related quality of life (HRQOL). Zinc supplementation has been effective with regard to altered nitrogen metabolism. AIM:To investigate the effectiveness of oral zinc supplementation on hepatic encephalopathy and HRQOL. METHODS:Seventy-nine cir...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2010.04448.x

    authors: Takuma Y,Nouso K,Makino Y,Hayashi M,Takahashi H

    更新日期:2010-11-01 00:00:00

  • Long-term prognosis in Crohn's disease: An epidemiological study of patients diagnosed more than 20 years ago in Cardiff.

    abstract:AIM:To investigate the incidence of death in patients diagnosed with Crohn's disease in Cardiff over 20 years ago. METHODS:The Cardiff database of patients with Crohn's disease contains data on all patients diagnosed there since 1934. Patients (394) diagnosed before 1 January 1985 were traced and their mortality statu...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.03132.x

    authors: Canavan C,Abrams KR,Hawthorne B,Mayberry JF

    更新日期:2007-01-01 00:00:00

  • Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels.

    abstract:BACKGROUND:Few studies have evaluated interferon and ribavirin therapy in hepatitis C virus-infected patients with persistently normal alanine aminotransferase (ALT) levels. AIM:To determine the efficacy and safety of combination therapy in this population, and to evaluate the impact of treatment on health-related qua...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.02819.x

    authors: Bini EJ,Mehandru S

    更新日期:2006-03-15 00:00:00

  • [13C]-pantoprazole breath test to predict CYP2C19 phenotype and efficacy of a proton pump inhibitor, lansoprazole.

    abstract:BACKGROUND:(13)CO(2) is produced on metabolism of (13)C-labelled-pantoprazole ([(13)C]-pantoprazole) by CYP2C19. AIM:To investigate whether the [(13)C]-pantoprazole breath test can predict CYP2C19 status and efficacy of proton pump inhibitors (PPIs) in Japanese. METHODS:We classified 110 healthy volunteers as rapid m...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2009.04044.x

    authors: Furuta T,Kodaira C,Nishino M,Yamade M,Sugimoto M,Ikuma M,Hishida A,Watanabe H,Umemura K

    更新日期:2009-08-01 00:00:00

  • Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations.

    abstract:BACKGROUND:Up to 80% of patients with Crohn's disease require an abdominal operation in their lifetime. As the use of vedolizumab is increasing for the treatment of Crohn's disease, it is important to understand its potential association with post-operative complications. AIM:We sought to compare 30-day postoperative ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.14459

    authors: Lightner AL,McKenna NP,Tse CS,Raffals LE,Loftus EV Jr,Mathis KL

    更新日期:2018-03-01 00:00:00

  • Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.

    abstract:BACKGROUND:Sofosbuvir, an oral NS5B nucleotide polymerase inhibitor, is indicated for the treatment of patients infected with hepatitis C virus (HCV). AIM:To evaluate the long-term health economic outcomes of sofosbuvir + pegylated interferon alfa/ribavirin (pegIFN/RBV) compared with current treatments in patients inf...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12871

    authors: Saab S,Gordon SC,Park H,Sulkowski M,Ahmed A,Younossi Z

    更新日期:2014-09-01 00:00:00

  • An analysis of the placebo effect in Crohn's disease over time.

    abstract:BACKGROUND:Randomized, placebo controlled trials are used to assess the efficacy of therapies for Crohn's disease. The placebo response and remission rates vary among studies. AIM:To analyse how the placebo response and remission rates in Crohn's trials have changed over time in the era of parenteral biologic therapie...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2009.04125.x

    authors: Gallahan WC,Case D,Bloomfeld RS

    更新日期:2010-01-01 00:00:00

  • Review article: intestinal failure.

    abstract::Intestinal failure is a specific disease entity resulting from intestinal resection or disease-associated malabsorption and characterized by the inability to maintain protein-energy, fluid, electrolyte or micronutrient balance. We performed a MEDLINE search (1966-2006) to identify relevant articles, using keywords int...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2006.02941.x

    authors: Lal S,Teubner A,Shaffer JL

    更新日期:2006-07-01 00:00:00

  • Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study.

    abstract:BACKGROUND:Data on tenofovir alafenamide fumarate (TAF) for preventing mother-to-child transmission of hepatitis B virus (HBV) are lacking. AIMS:To investigate the efficacy and safety of TAF therapy for preventing hepatitis B mother-to-child transmission. METHODS:Mothers with chronic HBV infection, positive for hepat...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/apt.16043

    authors: Ding Y,Cao L,Zhu L,Huang Y,Lin C,Wang Y,Liu Y,Sheng Q,Wang S,Fan J,Chen R,Gan W,Chen B,Pan CQ

    更新日期:2020-10-01 00:00:00

  • A controlled trial of ondansetron in the pruritus of cholestasis.

    abstract:BACKGROUND:In patients with pruritus of cholestasis, response to conventional drug treatment may be unsatisfactory. Activation of 5-hydroxytryptamine receptors on dermal sensory nerve-endings plays a role in the perception of pruritus. The 5-hydroxytryptamine(3) receptor antagonist, ondansetron, has been used in the tr...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2005.02430.x

    authors: O'Donohue JW,Pereira SP,Ashdown AC,Haigh CG,Wilkinson JR,Williams R

    更新日期:2005-04-15 00:00:00

  • Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation - implications for maternal dosing, foetal exposure, and safety for mother and child.

    abstract:BACKGROUND:With the global efforts to eradicate hepatitis C virus (HCV), treatment during pregnancy is becoming a priority for research as this, and maternal cure should reduce vertical transmission. However, as information on the efficacy and safety of direct-acting antivirals (DAAs) in pregnancy is generally lacking,...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.15476

    authors: Freriksen JJM,van Seyen M,Judd A,Gibb DM,Collins IJ,Greupink R,Russel FGM,Drenth JPH,Colbers A,Burger DM

    更新日期:2019-10-01 00:00:00

  • Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection.

    abstract:BACKGROUND:Patients with thalassaemia major depend on blood transfusions. In Italy, up to 80% of thalassaemia patients bear HCV antibodies due to HCV contaminated transfusions before 1990. Thalassaemia patients with HCV infection have high risk of developing HCC. Treatment based on Pegylated-IFN (Peg-IFN) and Ribavirin...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/apt.14197

    authors: Mangia A,Sarli R,Gamberini R,Piga A,Cenderello G,Piazzolla V,Santoro R,Caruso V,Quarta A,Ganga R,Copetti M,Forni G

    更新日期:2017-08-01 00:00:00

  • Clinical course and mortality by etiology of liver cirrhosis in Sweden: a population based, long-term follow-up study of 1317 patients.

    abstract:BACKGROUND:Liver cirrhosis is characterized by a silent phase until decompensation, which is defined by ascites, bleeding from esophageal varices or hepatic encephalopathy. AIM:To compare the clinical course, patterns of survival and causes of death by etiology during long-term follow-up in a large population-based co...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.15255

    authors: Nilsson E,Anderson H,Sargenti K,Lindgren S,Prytz H

    更新日期:2019-06-01 00:00:00

  • Effect of frequent dosing of an oral proton pump inhibitor on intragastric pH.

    abstract:BACKGROUND:Treatment with a continuous i.v. proton pump inhibitor is presumed to promote clot formation and stability by sustaining intragastric pH > or = 6. AIM:We postulated that very frequent oral dosing of proton pump inhibitors should simulate i.v. infusion and achieve similar pH control. METHODS:Twenty healthy ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.02933.x

    authors: Pais SA,Nathwani RA,Dhar V,Nowain A,Laine L

    更新日期:2006-06-01 00:00:00

  • Long-term use of acid suppression started inappropriately during hospitalization.

    abstract:BACKGROUND:Practitioners routinely misuse acid suppression medications on general medical floors and inappropriately continue the drug at discharge. AIMS:To: (i) retrospectively study the appropriateness of acid suppression use on the general medical floors; (ii) characterize the patient population discharged on unnec...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2005.02454.x

    authors: Zink DA,Pohlman M,Barnes M,Cannon ME

    更新日期:2005-05-15 00:00:00

  • Double-blind placebo-controlled multicentre studies of rebamipide, a gastroprotective drug, in the treatment of functional dyspepsia with or without Helicobacter pylori infection.

    abstract:BACKGROUND:Functional dyspepsia is a problem that is difficult to treat in clinical practice. AIM:To evaluate the efficacy and safety of rebamipide (a cytoprotective drug) in functional dyspepsia. METHODS:Patients with functional dyspepsia (n=557) were divided a priori into two studies by Helicobacter pylori status, ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1046/j.1365-2036.2001.01074.x

    authors: Talley NJ,Riff DS,Schwartz H,Marcuard SP

    更新日期:2001-10-01 00:00:00

  • Gastric restitution is inhibited by dexamethasone, which is reversed by hepatocyte growth factor and rebamipide.

    abstract:BACKGROUND:Glucocorticoids have been shown to induce peptic ulcers, especially when co-administered with NSAIDs. Hepatocyte growth factor (HGF) plays a role in gastric ulcer repair, facilitating the restitution of gastric mucosal epithelial cells. HGF expression is induced by PGs in gastric fibroblasts. We hypothesized...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.18.s1.19.x

    authors: Takahashi M,Takada H,Takagi K,Kataoka S,Soma R,Kuwayama H

    更新日期:2003-07-01 00:00:00

  • Review article: alginate-raft formulations in the treatment of heartburn and acid reflux.

    abstract::Alginate-based raft-forming formulations have been marketed word-wide for over 30 years under various brand names, including Gaviscon. They are used for the symptomatic treatment of heartburn and oesophagitis, and appear to act by a unique mechanism which differs from that of traditional antacids. In the presence of g...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2000.00759.x

    authors: Mandel KG,Daggy BP,Brodie DA,Jacoby HI

    更新日期:2000-06-01 00:00:00